Some six years after scoring an initial FDA nod in neuromyelitis optica spectrum disorder, Roche’s IL-6 receptor agonist Enspryng is muscling up to Roche's Tepezza in a key eye disease arena.
The FDA late this week endorsed Enspryng, also known as satralizumab, as a new treatment option for adults living with thyroid eye disease (TED), an autoimmune condition that can lead to swelling and bulging of the eyes, vision problems and pain.
The drug is delivered via below-the-skin injection, which can be done by the patient themselves or a caregiver from the comfort of home, according to an Oct. 16 release from Roche’s Genentech unit.
A rare condition, TED is estimated to affect roughly 155 out of every 100,000 people in the United States, introducing the risk of facial disfigurement and potential vision-complications if left untreated, Roche said.
Beyond the steroids used to control swelling in TED patients, the current treatment landscape is dominated by Amgen’s IGF-1R inhibitor Tepezza—which generated $1.9 billion in 2025 sales—while Viridian Therapeutics just snared a green light for its own TED challenger in similarly-classed Lumvoa back in June.
Bringing a new mechanism to the table, meanwhile, Enspryng was formulated to bind both soluble and membrane-bound interleukin-6 receptors, in turn inhibiting the IL-6 mediated signaling that Roche has flagged as a key inflammation pathway.
The drug’s original 2020 nod in in neuromyelitis optica spectrum disorder (NMSOD)—a rare and potentially devastating autoimmune condition that can cause blindness, paralysis and nerve pain—was a first for the IL-6 receptor agonist class as well.
Roche relied on results from its phase 3 SatraGO program to secure the new TED approval, though Enspryng’s performance across the pair of trials involved was somewhat mixed, with the SatroGo-1 study failing to meet its pre-specified primary efficacy endpoint at the 24-week mark.
The drug fared better in SatraGO-2, in which 52.9% of patients who got Enspryng achieved a significant and clinically meaningful difference in proptosis response—referring to the bulging of one or both eyes—compared to 23.4% of those who received placebo.
For the reduction of diplopia, or double vision, in SatraGo-2, Enspryng helped chart meaningful improvements in more than 60% of patients, versus a score of 25.8% in the trial’s control arm.
Those results drew from the study’s active TED population, with Roche noting in its release that the readout in the overall population, which included both active and chronic patients, was “consistent.”
“Today’s FDA approval of Enspryng provides an important new option for people with thyroid eye disease, who have long faced limited treatment choices,” said Levi Garraway, M.D., Ph.D., Roche’s chief medical officer and product development chief, in a statement.
Apart from bringing a new mechanism of action to bear, Enspryng’s self-injection option could carry a serious convenience edge over Tepezza and Lumvoa, both of which are given via infusion.
With Viridian’s Lumvoa approval earlier this summer, the company highlighted the fact that its approval applied to adults with active or chronic TED, making it the first IGF-1R inhibitor cleared in both forms of the disease—a potential advantage over Tepezza.
The company also spotlighted the shorter infusion time on Lumvoa—at 30 to 40 minutes versus around an hour on Tepezza—plus a shorter overall treatment period of 12 weeks, too.
Another self-admin win
Meanwhile, adherence and convenience appeared top of mind at the FDA this week, as the U.S. regulator also handed down an approval for a new autoinjector format of UCB’s C5 inhibitor for generalized myasthenia gravis (gMG), Zilbrysq.
As in the case of Enspryng, UCB’s subcutaneous Zilbrysq formulation can be received beyond the confines of the doctor’s office or infusion clinic.
The new nod marks the second for a self-administration option for Zilbrysq, which was first approved by the FDA for gMG in Oct. 2023, and which also comes in the form of a pre-filled syringe that can be used on one’s own.
UCB says it expects to launch its autoinjector in 2027’s first quarter.
With the thumbs up, UCB figures it now has the answer to “a question on which we've been relentlessly focused: How do we continue to improve an already effective therapy for daily use?" said Kimberly Moran, Ph.D., SVP and head of rare diseases for the U.S. at UCB, in a statement.